Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 25844069
Jang SH, Jun CD, Park ZY (2015) Label-free quantitative phosphorylation analysis of human transgelin2 in Jurkat T cells reveals distinct phosphorylation patterns under PKA and PKC activation conditions. Proteome Sci 13, 14 25844069
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S11-p - TAGLN2 (human)
Modsite: rGPAyGLsREVQQkI SwissProt Entrez-Gene
Orthologous residues
TAGLN2 (human): S11‑p, TAGLN2 (mouse): S11‑p, TAGLN2 (rat): S11‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, T cell leukemia
Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCA (human) pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
calyculin_A increase
phorbol_ester increase

T84-p - TAGLN2 (human)
Modsite: VkkIQAstMAFkQME SwissProt Entrez-Gene
Orthologous residues
TAGLN2 (human): T84‑p, TAGLN2 (mouse): S84‑p, TAGLN2 (rat): T84‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, T cell leukemia
Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
calyculin_A increase

S163-p - TAGLN2 (human)
Modsite: kENPRNFsDNQLQEG SwissProt Entrez-Gene
Orthologous residues
TAGLN2 (human): S163‑p, TAGLN2 (mouse): S163‑p, TAGLN2 (rat): S163‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, T cell leukemia
Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKACA (human) pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
calyculin_A increase
colforsin increase

T180-p - TAGLN2 (human)
Modsite: VIGLQMGtNrGAsQA SwissProt Entrez-Gene
Orthologous residues
TAGLN2 (human): T180‑p, TAGLN2 (mouse): T180‑p, TAGLN2 (rat): T180‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, T cell leukemia
Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCA (human) pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
calyculin_A increase
phorbol_ester increase

S185-p - TAGLN2 (human)
Modsite: MGtNrGAsQAGMtGy SwissProt Entrez-Gene
Orthologous residues
TAGLN2 (human): S185‑p, TAGLN2 (mouse): S185‑p, TAGLN2 (rat): S185‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, T cell leukemia
Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCA (human) pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
calyculin_A increase
phorbol_ester increase